Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension. A randomised, single blinded clinical trial
Latest Information Update: 20 Aug 2024
Price :
$35 *
At a glance
- Drugs Terlipressin (Primary) ; Octreotide
- Indications Liver cirrhosis; Portal hypertension
- Focus Pharmacodynamics
- Acronyms INFUTER
- 14 May 2020 New trial record